Tuesday, January 19, 2021 7:40:22 PM
I interpret this as quite a bit of confidence that lenzilumab deters progression to ventilation. After all, the p value on that exact endpoint was 0.06 in the case control trial (though only out to 18 days, but I would argue you far more likely to lose more in the control group over days 19-28 than the lenzilumab group), and that was a *TINY* study!
If you extrapolate that out over 500+, the p value is likely to be way way lower than 0.05. In other words, that would mean the primary endpoint hits.
This is all good to me.
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM